News | November 14, 2024
AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
We now rank 3rd in pharmaceutical production by volume and 14th by value
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Campaign launched to spread awareness regarding dengue prevention and control
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Subscribe To Our Newsletter & Stay Updated
